MedTrace Logo

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

NCT01926977 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-03-03

Study results available
· View outcomes & findings →

Summary

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

Ranibizumab 0.5mg

Patient will receive intravitreal injection of Ranibizumab 0.5mg.

DRUG

Aflibercept 2.0mg

Patients will receive intravitreal injection of Aflibercept 2.0mg.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Arshad Khanani

    lead OTHER

Principal Investigators

  • Arshad M Khanani, MD · Sierra Eye Associates

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926977 on ClinicalTrials.gov